Researchers released a consensus statement with recommendations to update T cell nomenclature and improve communication ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have ...
The results of the study could improve immunotherapy treatment for patients with colorectal and other barrier-tissue cancers.
On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...
It develops from the abnormal multiplication of T cells, or T-lymphocytes, a type of white blood cell essential for immune system function. The specific treatment course and prognosis for T-cell ...
Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
In most solid tumors, high numbers of regulatory T (Treg) cells are associated with poorer outcomes because they dampen the immune system's ability to fight against a tumor.
Saved from precursor B-cell acute lymphoblastic leukemia, the Nobel Prize winning CAR T-cell therapy gave Bryn Ailinger a very merry Christmas ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback